DPP9 Comes of Age: Highly Selective Inhibitors Promise New Therapeutic Opportunities

Dipeptidyl peptidase-like protein 9 (DPP9) is emerging as a promising drug target for the treatment of hematological diseases. Two novel DPP9 inhibitors with nanomolar affinity and unprecedented selectivity to DPP9 over DPP8 have been discovered, paving the way for future progress in DPP9-mediated treatments.

Automated summary

Dipeptidyl peptidase-like protein 9 (DPP9) is a promising drug target for hematological diseases. Two novel DPP9 inhibitors with nanomolar affinity and unprecedented selectivity over DPP8 have been discovered, opening the way for future DPP9-mediated treatments.